<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100427003813N13</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-03-06</date_registration>
      <primary_sponsor>Babol University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effects of two incision designs; Double flap and Periosteal releasing, on soft tissue changes following guided bone regeneration (GBR)</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effects of two incision designs; Double flap and Periosteal releasing, on soft tissue changes following guided bone regeneration, in patients with horizontal ridge defect on posterior mandible</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>24</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67690</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: To randomize the samples, the option of generating random numbers on the kitset.ir site was used. For this purpose, random numbers from 1 to 24 was generated as follows, the first half of which case number will be operated by Double flap incision (DFI) method and the second half by Periosteal releasing incision (PRI) method.
In the checklist of each patient, only one number is written and the surgical technique used is not specified, so neither the patient nor the examiner knows about the surgical technique used, Blinding description: In this study, the participant (patient) and the examiner who performs the examination in the follow-up appointments and records the results in the data sheet, do not know which group the patient is in and which surgical technique was used for the patient, because the type of technique will not be recorded in the patient's data sheet, and patients will only be identified by a number and from the appearance of the surgical site, the type of technique cannot be recognized. so the study is double-blinded. The only person who knows the surgical technique is the surgeon, who is not involved in recording the results.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Severe horizontal alveolar bone deformity(Seibert Class I).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The surgical method adopted in this group to reduce tension for flap advancement includes partial thickness flap elevation, which leaves the periosteal layer on the edentulous ridge and separates the mucosal layer of the flap. The periosteal layer of the flap stabilizes the reconstruction site using periosteal sutures. A crestal incision will be made with a vertical releasing incision 2 mm from the most distal tooth  with a #15 blade. The crestal incision will be extended distal to the flap to avoid traction. Then a partial thickness flap that separates the mucosal flap from the periosteum that covers the alveolar bone, will be made on the buccal side. After sufficient separation between the external (mucosal) and internal (periosteal) flaps, the periosteal flap will be raised from the bone surface. Then a full thickness lingual mucoperiosteal flap is raised. After that, a 1˟2 cm collagen membrane from Kish Tissue Replicator will be used to create a space free of soft tissue. The bone defect will be filled with half a cc of freeze-dried mineralized bone allograft from Kish Tissue Replicator. The periosteal flap will be placed and fixed with 4-0 Vicryl sutures using two horizontal sutures. Intervention 2: Control group: In this group, the gold standard method, periosteal releasing incision, will be used for surgery. In the missing tooth site with horizontal bone defect, an incision will be made using a 15 blade to divide the gingival flap into 2 equal parts. The flap is elevated full thickness on both buccal and lingual sides. Then, to free the flap from tension, a periosteal incision is made with a 15 blade on both buccal and lingual sides. Then, as in Group 1, a collagen membrane will be used to create a soft tissue-free space. The bone defect will be filled with freeze-dried mineralized bone graft. The flap will be fixed with 4-0 vicryl figure C sutures.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after de-identifying individuals

When:
The access period starts 6 months after the results are published

To whom:
The data will be available to researchers working in academic and scientific institutions or people working in industry

Conditions:
It is possible to use data or documents for further studies or to choose a more appropriate treatment method for patients

Where to obtain:
To receive documents or data, contact Dr. Niloofar Jenabian at the following email address.
njenabian@hotmail.com

How to obtain:
Wait for a reply by sending a request email to the above address

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Niloofar Jenabian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University of medical sciences, Ganj afrooz Street, Babol</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4717647745</zip>
        <telephone>+98 11 1229 1408</telephone>
        <email>n.jenabian@mubabol.ac.ir</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Niloofar Jenabian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University of medical sciences, Ganj afrooz Street, Babol</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4717647745</zip>
        <telephone>+98 11 1229 1408</telephone>
        <email>n.jenabian@mubabol.ac.ir</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Has severe horizontal alveolar bone deformity(Seibert Class I) and requires guided bone regeneration treatment in the posterior region of the mandible</inclusion_criteria>
      <agemin>21 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of smoking
History of systemic disease
History of unexplained allergies</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The surgical method adopted in this group to reduce tension for flap advancement includes partial thickness flap elevation, which leaves the periosteal layer on the edentulous ridge and separates the mucosal layer of the flap. The periosteal layer of the flap stabilizes the reconstruction site using periosteal sutures. A crestal incision will be made with a vertical releasing incision 2 mm from the most distal tooth  with a #15 blade. The crestal incision will be extended distal to the flap to avoid traction. Then a partial thickness flap that separates the mucosal flap from the periosteum that covers the alveolar bone, will be made on the buccal side. After sufficient separation between the external (mucosal) and internal (periosteal) flaps, the periosteal flap will be raised from the bone surface. Then a full thickness lingual mucoperiosteal flap is raised. After that, a 1˟2 cm collagen membrane from Kish Tissue Replicator will be used to create a space free of soft tissue. The bone defect will be filled with half a cc of freeze-dried mineralized bone allograft from Kish Tissue Replicator. The periosteal flap will be placed and fixed with 4-0 Vicryl sutures using two horizontal sutures.</i_keyword>
      <i_keyword>Control group: In this group, the gold standard method, periosteal releasing incision, will be used for surgery. In the missing tooth site with horizontal bone defect, an incision will be made using a 15 blade to divide the gingival flap into 2 equal parts. The flap is elevated full thickness on both buccal and lingual sides. Then, to free the flap from tension, a periosteal incision is made with a 15 blade on both buccal and lingual sides. Then, as in Group 1, a collagen membrane will be used to create a soft tissue-free space. The bone defect will be filled with freeze-dried mineralized bone graft. The flap will be fixed with 4-0 vicryl figure C sutures.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The amount of flap advancement during surgery. Timepoint: During surgery, before tension freeing the flap with one of techniques and after that. Method of measurement: Measuring the amount of the flap advancement compared to its base during surgery with UNC-15 probe.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Membrane exposure. Timepoint: 3rd day and 1, 2, 4, 12 and 24 weeks after surgery. Method of measurement: Did membrane exposed in the mouth in follow-up stages or not?.</sec_outcome>
      <sec_outcome>Infection. Timepoint: 3rd day and 1, 2, 4, 12 and 24 weeks after surgery. Method of measurement: Is there pus at the surgical site in the follow-up stages or not?.</sec_outcome>
      <sec_outcome>Paraesthesia. Timepoint: 3rd day and 1, 2, 4, 12 and 24 weeks after surgery. Method of measurement: Is there sensory disorders related to surgery in the follow-up stages or not?.</sec_outcome>
      <sec_outcome>Continuous discomfort. Timepoint: 3rd day and 1, 2, 4, 12 and 24 weeks after surgery. Method of measurement: Is there any expression of discomfort in the surgical area by the patient in the follow-up stages or not?.</sec_outcome>
      <sec_outcome>Pain. Timepoint: 3rd day and 1, 2, 4, 12 and 24 weeks after surgery. Method of measurement: by Visual Analogue Scale.</sec_outcome>
      <sec_outcome>Swelling. Timepoint: 3rd day and 1, 2, 4, 12 and 24 weeks after surgery. Method of measurement: by Visual Analogue Scale.</sec_outcome>
      <sec_outcome>Bleeding. Timepoint: 3rd day and 1, 2, 4, 12 and 24 weeks after surgery. Method of measurement: by Visual Analogue Scale.</sec_outcome>
      <sec_outcome>Healing of surgery site. Timepoint: 3rd day and 1, 2, 4, 12 and 24 weeks after surgery. Method of measurement: by Wound healing index.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Babol University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-11-28</approval_date>
        <contact_name>Ethics committee of Babol University of Medical Sciences</contact_name>
        <contact_address>University of medical sciences, Ganj afrooz street, Babol Babol Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
